Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 14

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 14
---
., or DARA, in 2015 at a weighted average exercise price of $981.91;       
 and                                                                                                |

| · | warrants,                                                                                           
 including pre-funded warrants, exercisable for 48,848 Depositary Shares (representing 4,884,800,000 
 Ordinary Shares), at a weighted average exercise price of $402.20 per Depositary Share.             |

| 12 |

<div align='center'>SELLING SHAREHOLDERS</div>

This prospectus covers
the possible resale from time to time by the selling shareholders identified in the table below of Ordinary Shares represented by Depositary
Shares issuable upon the exercise of the December 2023 Private Placement Pre-Funded Warrants (referred to in this section collectively
and individually as the “warrants”). The selling shareholders may sell some, all or none of their Ordinary Shares represented
by Depositary Shares. We do not know how long the selling shareholders will hold the warrants, whether any will exercise the warrants,
and upon such exercise, how long such selling shareholders will hold the Ordinary Shares represented by Depositary Shares before selling
them, and we currently have no agreements, arrangements or understandings with the selling shareholders regarding the sale of any of
the shares.

The table below lists
the selling shareholders and other information regarding the beneficial ownership of the Ordinary Shares represented by Depositary Shares
by each of the selling shareholders. The second column lists the number of Ordinary Shares represented by Depositary Shares beneficially
owned by each selling shareholder, based on its ownership of Depositary Shares and warrants to purchase Depositary Shares, as of November
1, 2025, assuming exercise of the warrants held by the selling shareholders on that date, without regard to any limitations on conversions
or exercises. The third column lists the maximum number of Ordinary Shares represented by Depositary Shares being offered in this prospectus
by the selling shareholders. The fourth column lists the amount of Ordinary Shares represented by Depositary Shares owned after the offering,
assuming the sale of all of the Ordinary Shares represented by Depositary Shares offered by the selling shareholders pursuant to this
prospectus, and without regard to any limitations on conversions or exercises.

In accordance with the
terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i)
the number of Ordinary Shares issued to the selling shareholders in the December 2023 Private Placement and the number of Ordinary Shares
issued to the selling shareholders upon the exercise of the warrants issued